Ulcerative colitis worsened after Clostridium difficile infection: Efficacy of infliximab

World Journal of Gastroenterology

Volumn 20, Issue 17, 2014, Pages 5135-5140

  Seicean, Andrada ^a   Moldovan Pop, Anca ^a   Seicean, Radu ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Clostridium difficile; Inflammatory bowel disease; Infliximab; Trough level; Ulcerative colitis

Indexed keywords

INFLIXIMAB; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; MALE; RISK FACTOR; TREATMENT OUTCOME; ULCERATIVE COLITIS; BIOPSY; COLITIS, ULCERATIVE; COLONOSCOPY; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOPSY; CLOSTRIDIUM DIFFICILE; COLITIS, ULCERATIVE; COLONOSCOPY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL AGENTS; HUMANS; MALE; RECURRENCE; TREATMENT OUTCOME;

EID: 84899814696     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i17.5135     Document Type: Article

References (35)

1. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-1450 [PMID: 18513271 DOI: 10.1111/j.1572-0241.2007.01780.x]
2. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-351 [PMID: 17368234 DOI: 10.1016/ j.cgh.2006.12.028]
3. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-344 [PMID: 17368233 DOI: 10.1016/j.cgh.2006.12.027]
4. Kariv R, Navaneethan U, Venkatesh PG, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohns Colitis 2011; 5: 34-40 [PMID: 21272802 DOI: 10.1016/j.crohns.2010.09.007]
5. Ricciardi R, Ogilvie JW, Roberts PL, Marcello PW, Concannon TW, Baxter NN. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum 2009; 52: 40-45 [PMID: 19273954 DOI: 10.1007/DCR.0b013e31819733fd]
6. Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol 2009; 7: 981-987 [PMID: 19523534 DOI: 10.1016/j.cgh.2009.05.031]
7. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-264 [PMID: 19438424 DOI: 10.1111/ j.1365-2036.2009.04037.x]
8. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease. Am J Gastroenterol 2010; 105: 2040-2049 [PMID: 20389295 DOI: 10.1038/ajg.2010.142]
9. Johnson S, Gerding DN. Clostridium difficile--associated diarrhea. Clin Infect Dis 1998; 26: 1027-1034; quiz 1035-1036 [PMID: 9597221 DOI: 10.1086/520276]
10. Ananthakrishnan AN, Oxford EC, Nguyen DD, Sauk J, Yajnik V, Xavier RJ. Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 522-530 [PMID: 23848254 DOI: 10.1111/apt.12425]
11. Shen B, Remzi FH, Fazio VW. Fulminant Clostridium difficile-associated pouchitis with a fatal outcome. Nat Rev Gastroenterol Hepatol 2009; 6: 492-495 [PMID: 19654602 DOI: 10.1038/nrgastro.2009.105]
12. Vesoulis Z, Williams G, Matthews B. Pseudomembranous enteritis after proctocolectomy: report of a case. Dis Colon Rectum 2000; 43: 551-554 [PMID: 10789757]
13. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16: 775-778 [PMID: 15256979]
14. Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003; 115: 543-546 [PMID: 14599633 DOI: 10.1016/S0002-9343(03)00420-0]
15. Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, Pardi DS. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11: 1466-1471 [PMID: 23702192 DOI: 10.1016/j.cgh.2013.04.050]
16. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-498; quiz 499 [PMID: 23439232 DOI: 10.1038/ ajg.2013.4]
17. Nomura K, Fujimoto Y, Yamashita M, Morimoto Y, Ohshiro M, Sato K, Oyake T, Kowata S, Konishi H, Yoshikawa T, Ishida Y, Taniwaki M. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009; 44: 74-78 [PMID: 18781540 DOI: 10.1080/00365520802321238]
18. Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, de Miera IS, Reinisch W, Chowers Y, Moran GW. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis 2010; 4: 194-198 [PMID: 21122505 DOI: 10.1016/ j.crohns.2009.11.001]
19. Arnold C, von Sanden S, Theilacker C, Blum HE. Ulcerous colitis and infection with cytomegalovirus, herpes simplex virus and clostridium difficile. Z Gastroenterol 2008; 46: 780-783 [PMID: 18759202 DOI: 10.1055/s-2008-1027154]
20. Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1051-1063 [PMID: 22613901 DOI: 10.1038/ ajg.2012.89]
21. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010; 55: 415-420 [PMID: 19255850 DOI: 10.1007/s10620-009-0749-9]
22. Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis 2012; 6: 330-336 [PMID: 22405170 DOI: 10.1016/ j.crohns.2011.09.005]
23. Osman KA, Ahmed MH, Hamad MA, Mathur D. Emergency colectomy for fulminant Clostridium difficile colitis: Striking the right balance. Scand J Gastroenterol 2011; 46: 1222-1227 [PMID: 21843039 DOI: 10.3109/00365521.2011.605469]
24. Chiplunker A, Ananthakrishnan AN, Beaulieu DB, Naik AS, Zadvormova Y, Skaros S, Johnson K, Perera LP, Binion DG, Issa M. Long-term impact of Clostridium difficile on inflammatory bowel disease. Gastroenterology 2009; 136 Suppl 1: A-199
25. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013; 7: 107-112 [PMID: 22440891 DOI: 10.1016/ j.crohns.2012.02.015]
26. Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1322-1331 [PMID: 21517920 DOI: 10.1111/j.1365-2036.2011.04661.x]
27. Maroo S, Lamont JT. Recurrent clostridium difficile. Gastroenterology 2006; 130: 1311-1316 [PMID: 16618421 DOI: 10.1053/j.gastro.2006.02.044]
28. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-1590 [PMID: 15889354 DOI: 10.1086/430311]
29. Kelly CP. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA 2009; 301: 954-962 [PMID: 19190304 DOI: 10.1001/ jama.2009.171]
30. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-1049 [PMID: 21871249 DOI: 10.1016/j.cgh.2011.08.014]
31. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310-318 [PMID: 21087119 DOI: 10.3109/00365521.2010.536254]
32. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54 [PMID: 19651627 DOI: 10.1136/gut.2009.183095]
33. Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-971 [PMID: 23419382 DOI: 10.1038/ajg.2013.12]
34. Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D, Colombel JF, Allez M. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-1206 [PMID: 22127789 DOI: 10.1002/ibd.21839]
35. Kopylov U, Sasson G, Geyshis B, Oikawa MT, Barshack I, Eliakim R, Ben-Horin S. Cytomegalovirus positive ulcerative colitis: A single center experience and literature review. World J Gastrointest Pathophysiol 2013; 4: 18-23 [PMID: 23596551 DOI: 10.4291/wjgp.v4.i1.18]